This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hirsch, A. T Articles by Duprez, D. Search for Related Content PubMed PubMed Citation Articles by Hirsch, A. T Articles by Duprez, D. Social Bookmarking                         What's this?

The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease

Vascular Medicine Program, Minneapolis Heart Institute, and Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, MN, USA, hirsc005{at}umn.edu

Daniel Duprez

Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN, USA

Peripheral arterial disease (PAD) is associated with significant morbidity and mortality, and yet remains under-recognized and under-treated. Atherosclerosis is the most common cause of lower extremity PAD and pharmacological interventions that alter this central pathogenic role of atherosclerosis may alter the natural history of PAD. There is growing evidence that the renin-angiotensin system (RAS) is a significant mediator of this disease process and that treatment with angiotensin-converting enzyme (ACE) inhibitors is associated with vasculoprotective effects that are independent of the antihypertensive properties of these agents. Numerous lines of evidence suggest that ACE inhibitors directly inhibit the atherosclerotic process and improve vascular endothelial function. In patients with PAD, ACE inhibitors have been shown to improve peripheral circulation as measured by peripheral arterial blood pressure and by increases in peripheral blood flow. Preliminary evidence suggests that ACE inhibitors might improve clinical symptoms in patients with PAD. Recent evidence has confirmed that ACE inhibition is associated with a decrease in morbidity and mortality in patients with arterial disease without left ventricular dysfunction; this benefit was at least as great for the subset of patients with PAD. Overall, these data support a significant role for the RAS in the pathogenesis of all atherosclerotic diseases (including PAD) and suggest that the benefit is independent of the blood pressure lowering properties of these agents. These studies suggest that ACE inhibitor therapy should be considered in the routine management of individuals with PAD, regardless of whether they have hypertension or left ventricular dysfunction.

Key Words: angiotensin-converting enzyme inhibitors • review • vascular diseases

Vascular Medicine, Vol. 8, No. 4, 273-278 (2003)
DOI: 10.1191/1358863x03vm502oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. I. Ahmed, W. S. Aronow, M. H. Criqui, I. Aban, T. E. Love, E. J. Eichhorn, and A. Ahmed Effects of Peripheral Arterial Disease on Outcomes in Advanced Chronic Systolic Heart Failure: A Propensity-Matched Study Circ Heart Fail, January 1, 2010; 3(1): 118 - 124. [Abstract] [Full Text] [PDF]

				L. M. Steffen, D. A. Duprez, J. L. Boucher, A. G. Ershow, and A. T. Hirsch Management of Peripheral Arterial Disease Diabetes Spectr, July 1, 2008; 21(3): 171 - 177. [Abstract] [Full Text] [PDF]

				H. H.H. Feringa, S. E. Karagiannis, M. Chonchol, R. Vidakovic, P. G. Noordzij, A. Elhendy, R. T. van Domburg, G. Welten, O. Schouten, J. J. Bax, et al. Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1872 - 1879. [Abstract] [Full Text] [PDF]

				H. H.H. Feringa, V. H. van Waning, J. J. Bax, A. Elhendy, E. Boersma, O. Schouten, W. Galal, R. V. Vidakovic, M. J. Tangelder, and D. Poldermans Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1182 - 1187. [Abstract] [Full Text] [PDF]

				H. H. H. Feringa, J. J. Bax, O. Schouten, and D. Poldermans Protecting the Heart with Cardiac Medication in Patients with Left Ventricular Dysfunction Undergoing Major Noncardiac Vascular Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2006; 10(1): 25 - 31. [Abstract] [PDF]

				S. S. Daskalopoulou, V. G. Athyros, G. Hamilton, and D. P. Mikhailidis Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 145 - 147. [PDF]